BNT162b2 vaccines
[용어속성] Molecule
Antibody Response to SARS-CoV-2 Vaccines in People with Severe Obesity
중증 비만 환자의 SARS-CoV-2 백신에 대한 항체 반응
Article
[키워드] age
antibody
antibody level
antibody levels
Antibody Response
Antibody titer
Antibody titers
anticipated
Antigen
blood sample
Blood samples
BMI
BNT162b2
BNT162b2 mRNA
BNT162b2 vaccine
BNT162b2 vaccines
consecutive patient
Control
control group
CoronaVac
Course
COVID-19
COVID-19 vaccination
determined by
disease
domain
dose
dose of vaccination
Effectiveness
enrolled
female
IgG antibody
IgG antibody titers
inactivated
individual
Infection
information
male
mRNA
normal weight
not significantly different
obesity
of BNT162b2
Patient
presenting
Quantitative
recruited
reduced
response
SARS-CoV-2
SARS-CoV-2 IgG
SARS-CoV-2 IgG antibody
SARS-COV-2 infection
SARS-CoV-2 spike antigen
SARS-CoV-2 vaccination
SARS-CoV-2 vaccine
serological
Severe obesity
significantly
significantly higher
significantly lower
spike-protein
subject
vaccination
Vaccine
Vaccines
vulnerable population
was performed
weight control
were measured
[DOI] 10.1007/s11695-022-06181-y PMC 바로가기 [Article Type] Article
[DOI] 10.1007/s11695-022-06181-y PMC 바로가기 [Article Type] Article
A case series of severe breakthrough infections observed in nine patients with COVID-19 in a southwestern German university hospital
독일 남서부 대학 병원에서 9명의 COVID-19 환자에서 관찰된 일련의 심각한 돌발 감염 사례
Article
[키워드] addition
advanced age
age
analyzed
avoidance
B.1.617.2
behavioural
BNT162b2
BNT162b2 vaccines
booster vaccination
Breakthrough infection
cardiorespiratory
case sery
Comorbidities
Complete
Course
COVID-19
death
delta variant
disease
dose
effective
Face masks
FIVE
high risk
high-risk area
high-risk areas
Hospitalization
Hospitalized
hospitalized patient
immunization
Increased
Infection
Intensive
intensive care
lack
measure
Measures
median
median age
nine
of BNT162b2
Patient
patients
patients died
patients with COVID-19
Pfizer-BioNTech
preventive measures
Protective
question
raise
risk factor
Risk factors
SARS-CoV-2
suffered
symptom onset
Travel
two patients
U/mL
university hospital
vaccination
Vaccine
Vaccine breakthrough
[DOI] 10.1007/s15010-022-01797-9 PMC 바로가기 [Article Type] Article
[DOI] 10.1007/s15010-022-01797-9 PMC 바로가기 [Article Type] Article
Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients
면역 저하 환자의 COVID-19 mRNA 백신에 의한 우려 변종에 대한 체액 반응
Article
[키워드] 2019-nCoV
Against
age
All participant
All participants
Alpha
anti-spike antibody
Antibody titer
Antibody titers
association
Autoimmune disease
Autoimmune diseases
best
Beta
Beta variant
binding
BNT162b2
BNT162b2 vaccine
BNT162b2 vaccines
Cancer
cancers
circulating
concern
conducted
COVID-19
decrease
Delta
delta variant
Delta variants
dose
Effectiveness
elicited
enrolled
female
Gamma
greater
healthy control
healthy controls
hematologic
Humoral response
humoral responses
IgG
Immunocompromised patient
Immunocompromised patients
median
Messenger RNA
Moderna
mRNA
mRNA vaccine
mRNA-1273
NAb
NAb responses
NAbs
nCoV
neutralizing antibody
neutralizing antibody titers
outcome
participant
Participants
Patient
patient population
performed
persistence
Pfizer-BioNTech
Primary outcome
proportion
proportions
response
response to vaccination
responses against
SARS-CoV-2
SARS-CoV-2 variants
secondary outcome
solid cancers
solid organ
solid organ transplant
solid organ transplants
study group
the healthy
the patient
the SARS-CoV-2
Treatment
underlying disease
university
vaccination
vaccination schedule
Vaccine
Vaccines
variant
variants
variants of concern
VoC
VOCs
were measured
[DOI] 10.1001/jamaoncol.2022.0446 PMC 바로가기 [Article Type] Article
[DOI] 10.1001/jamaoncol.2022.0446 PMC 바로가기 [Article Type] Article
Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron
백신은 SARS-CoV-2 Omicron에 대해 고도로 보존된 세포 면역을 유도합니다
Article
[키워드] Ad26
Ad26.COV2.S
B.1.1.529
BNT162b2
BNT162b2 vaccine
BNT162b2 vaccines
CD4
CD8
cellular
cellular immune responses
cellular immunity
conserved
contribute
cross-reactivity
Delta
demonstrated
effector memory
elicit
elicited
evade
fraction
immune responses
immunological
individual
Infection
mutated
Neutralizing antibody response
neutralizing antibody responses
observation
omicron
Omicron variants
reduced
robust
SARS-CoV-2
SARS-COV-2 infection
severe disease
severe SARS
severe SARS-CoV-2
shown
Spike protein
subpopulations
T cell
T cell response
T cell responses
the SARS-CoV-2
These data
Vaccine
variant
variants
WA1/2020
[DOI] 10.1038/s41586-022-04465-y PMC 바로가기 [Article Type] Article
[DOI] 10.1038/s41586-022-04465-y PMC 바로가기 [Article Type] Article
Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England
Research Article
[키워드] absolute increase
Accuracy
adjusted
Adults
age
age and sex
analysed
Analysis
anticoagulant medication
antiplatelet
Asian
association
black
blood pressure
BNT162b2
BNT162b2 vaccines
case finding
ChAdOx1
ChAdOx1-S
coded
cohort study
confidence interval
confounding factors
Coronavirus infection
covariate
covariates
COVID-19
COVID-19 mortality
COVID-19 vaccination
COVID-19 vaccine
COVID-19 vaccines
Deprivation
diabetes
diagnostic
dose
DVT
Effect
effort
Electronic health record
Electronic health records
England
estimate
estimates
event
first vaccination
Frequency
hazard ratio
healthcare
Hospital admission
hospitalisation
hospitalised
HRs
hypertension
identify
IMPROVE
incidence
incidence rate
increase in
increased risk
increases in
limitation
medication
morbidity
morbidity and mortality
Myocardial infarction
outcome
performed
Platelet
population level
population-based cohort
Positive predictive value
prevaccination
Rate
reducing
reported
researcher
residual confounding
risk
selected
Sex
smoking
stroke
therapy
threshold
thrombosis
thrombotic event
Thrombotic events
vaccination
Vaccine
Vaccines
venous
Venous thrombosis
white
William
[DOI] 10.1371/journal.pmed.1003926 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1371/journal.pmed.1003926 PMC 바로가기 [Article Type] Research Article
Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines
Covid-19 백신에 의한 경증 및 중증 질병에 대한 보호 기간
Article
[키워드] 95% CI
95% confidence interval
acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
Adults
age
Alpha
B.1.1.7
B.1.617.2
BNT162b2
BNT162b2 vaccine
BNT162b2 vaccines
Case-control
cause
ChAdOx1
ChAdOx1 nCoV-19
ChAdOx1-S
clinical risk
clinically
condition
coronavirus
coronavirus disease
Coronavirus disease 2019
death
delta variant
dose
Duration
effective
Effectiveness
England
greater
healthy
Hospitalization
less
medical condition
Older
peaked
protection
real-world data
receipt
SARS-CoV-2
second dose
severe acute respiratory syndrome Coronavirus
severe disease
shown
status
symptomatic COVID-19
the vaccine
United Kingdom
vaccination
Vaccine
vaccine dose
variant
variants
virus
[DOI] 10.1056/NEJMoa2115481 PMC 바로가기 [Article Type] Article
[DOI] 10.1056/NEJMoa2115481 PMC 바로가기 [Article Type] Article
Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination
델타의 중화 감소 (B.1.617.2) 예방 접종 후 SARS-COV-2 우려 변형
Research Article
[키워드] (Beta
accumulation
African
antibody
Antibody titre
antigenic
antigenic drift
antigenic profiles
assessment
Astra Zeneca
Author
B.1.351
B.1.617.1
B.1.617.2
bat
bats
Beta
BNT162b2
BNT162b2 vaccines
Booster vaccine
booster vaccines
ChAdOx1
changes in
collected
COVID-19
COVID19
death
decrease
decreases
Delta
delta variant
dose
effective
Effectiveness
Efficacy
elicited
evade
expressed
facilitate
fold
Fold changes
glycoprotein
groups
hospitalisation
Human
human cell
human cells
humans
Immunity
India
indicated
individual
Infection
Lineage
magnitude
Mutation
neutralisation
neutralise
Neutralising Antibodies
neutralising antibody titres
of BNT162b2
Pfizer
Pfizer/BioNTech
Prevent
profile
protective immune response
pseudoviruses
recipient
recipients
reduced
reduction
reduction in
reductions
reductions in
required
risk
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 variant
SARS-CoV-2 variants
SARS-CoV-2 virus
sensitivity
sera
Severe infection
shape
significantly higher
South
South Africa
spike glycoprotein
spike glycoproteins
Spike protein
subsequent
the spike protein
titre
vaccinated individuals
vaccination
Vaccine
vaccine efficacy
Vaccines
variant
variant B.1.617.2
variants
variants of concern
Viral
viral variant
Viral variants
virus
Virus spike
VOCs
while
with infection
with infections
Wuhan
Wuhan, China
[DOI] 10.1371/journal.ppat.1010022 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1371/journal.ppat.1010022 PMC 바로가기 [Article Type] Research Article
Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection
SARS-COV-2 mRNA 백신에 대한 체액 반응 : 과거 감염의 역할
Research Article
[키워드] antibody
Antibody titers
biologic
BNT162b2
BNT162b2 vaccine
BNT162b2 vaccines
booster
completion
decay
demonstrated
Department
detect
dose
enrolled
fire
first responders
Health Service
Humoral response
humoral responses
immune responses
immunoassay
implication
individual
individuals
infected individual
Infection
Los Angele
Los Angeles
magnitude
median
Microparticle
mRNA
mRNA vaccine
mRNA-1273
mRNA-based vaccine
mRNA-based vaccines
naïve
naïve individuals
NPI
pandemic
protective immune response
remains uncertain
required
respiratory
Responder
robust antibody response
robust antibody responses
role
SARS-CoV-2
SARS-CoV-2 spike
Severe acute respiratory syndrome
spike
subset
two-dose regimen
understanding
University of California
Vaccine
vaccine dose
vaccinee
vaccinees
was used
[DOI] 10.1371/journal.pone.0259703 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1371/journal.pone.0259703 PMC 바로가기 [Article Type] Research Article
Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study
nCoV-19 백신 접종 후 과응고의 부재: 관찰 파일럿 연구
Observational Study
[키워드] activating
Activation
ADP
age
aggregation
BNT162b2
BNT162b2 vaccine
BNT162b2 vaccines
Care
carriers
ChAdOx1
ChAdOx1 vaccine
ChAdOx1 vaccines
clinically
Coagulation
Cohort
comparable
control group
controls
COVID-19
COVID-19 vaccine
COVID-19 vaccines
eligible
endogenous
evaluated
fibrinogen
first dose
Gender
groups
Health
Health care
healthy subject
healthy subjects
hypercoagulability
hypercoagulable
induce
no difference
no differences
oral contraceptive
oral contraceptives
parameter
peptide
pilot study
plasma
Platelet
platelet aggregation
Platelet count
predisposition
professional
prothrombotic state
receptor
SARS-CoV-2
subject
thrombin
Thrombin generation
thrombin receptor
Thrombophilia
thrombosis
TRAP
university
vaccination
Vaccine
Volunteer
Whole blood
women
[DOI] 10.1016/j.thromres.2021.06.016 PMC 바로가기 [Article Type] Observational Study
[DOI] 10.1016/j.thromres.2021.06.016 PMC 바로가기 [Article Type] Observational Study